Natural Product (NP) Details
General Information of the NP (ID: NP6356) | |||||
---|---|---|---|---|---|
Name |
Vanillic acid
|
||||
Synonyms |
Vanillic acid; 4-HYDROXY-3-METHOXYBENZOIC ACID; 121-34-6; Acide vanillique; Benzoic acid, 4-hydroxy-3-methoxy-; p-Vanillic acid; 3-Methoxy-4-hydroxybenzoic acid; Vanillate; m-Anisic acid, 4-hydroxy-; Protocatechuic acid, 3-methyl ester; 4-hydroxy-3-methoxy-Benzoic acid; UNII-GM8Q3JM2Y8; 4-Hydroxy-3-methoxybenzoate; NSC 3987; MFCD00002551; NSC 674322; GM8Q3JM2Y8; CHEMBL120568; CHEBI:30816; 4-hydroxy-3-methoxy benzoic acid; NSC674322; VA; VA (VAN); 4-Hydroxy-3-methoxybenzoic acid, 97+%; VNL; 4-hydroxy-m-Anisic acid; EINECS 204-466-8; BRN 2208364; Vanillinsaure; p-Vanillate; Vanilic acid; AI3-19542; Vanillic Acid,(S); 4-hydroxy-m-Anisate; Vanillic acid (M2); Vanillic acid, 97%; PubChem19485; ACMC-1BPT2; bmse000486; bmse000614; bmse010205; WLN: QVR DQ CO1; 3-Methoxy-4-hydroxybenzoate; SCHEMBL26179; MLS000574833; 4-hydroxy-3-methoxy-Benzoate; 4-Hydroxy-3-methoxybenzoicacid; Vanillic acid, >=97%, FG; 4-hydroxy-3methoxy benzoic acid; DTXSID6059522; 4-hydroxyl-3-methoxybenzoic acid; NSC3987; 4- hydroxy-3-methoxybenzoic acid; HMS2197E16; Protocatechuic acid 3-methyl ester; ZINC338275; HY-N0708; NSC-3987; STR02334; ANW-17590; BBL011982; BDBM50337364; s5343; SBB008280; STL163472; AKOS000113195; CCG-266343; MCULE-2667517874; MP-2220; NSC-674322; NCGC00247610-01; AC-11841; AK-32998; BP-13246; SMR000156289; ST086485; SY001450; DB-003804; Vanillic acid, purum, >=97.0% (HPLC); AM20050239; CS-0009728; FT-0650155; C06672; Vanillic acid, Vetec(TM) reagent grade, 97%; 198598-EP2277877A1; Q419672; Q-201921; Z1741973874; Vanillic acid, certified reference material, TraceCERT(R); 3E9555E5-85F5-4FCE-A429-5182E959C6A3
Click to Show/Hide
|
||||
Species Origin | Angelica sinensis ... | Click to Show/Hide | |||
Angelica sinensis | |||||
Disease | Asthma [ICD-11: CA23] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C8H8O4
|
||||
PubChem CID | |||||
Canonical SMILES |
COC1=C(C=CC(=C1)C(=O)O)O
|
||||
InChI |
1S/C8H8O4/c1-12-7-4-5(8(10)11)2-3-6(7)9/h2-4,9H,1H3,(H,10,11)
|
||||
InChIKey |
WKOLLVMJNQIZCI-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 121-34-6
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | TLR4 | Molecule Info |
Pathway MAP
|
|
In-vivo Model | Male Wistar albino rats weighing 200 +/- 20 g were used in this study. | |||||
Experimental
Result(s) |
VA exerts cardioprotective effects against DOX-induced cardiotoxicity by decreasing oxidative stress and biomarkers of cardiotoxicity, suppression of TLR4 signaling and consequently inflammation pathway. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | CCAAT/enhancer-binding alpha (CEBPA) | Molecule Info | [3] | |
PPAR-gamma (PPARG) | Molecule Info | [3] | ||
KEGG Pathway | PPAR signaling pathway | Click to Show/Hide | ||
2 | AMPK signaling pathway | |||
3 | Osteoclast differentiation | |||
4 | Huntington's disease | |||
5 | Pathways in cancer | |||
6 | Transcriptional misregulation in cancer | |||
7 | Thyroid cancer | |||
NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
2 | TGF_beta_Receptor Signaling Pathway | |||
3 | Leptin Signaling Pathway | |||
Panther Pathway | CCKR signaling map ST | Click to Show/Hide | ||
Pathway Interaction Database | Noncanonical Wnt signaling pathway | Click to Show/Hide | ||
2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
3 | Signaling events mediated by HDAC Class I | |||
4 | RXR and RAR heterodimerization with other nuclear receptor | |||
5 | Regulation of retinoblastoma protein | |||
Reactome | PPARA activates gene expression | Click to Show/Hide | ||
2 | Transcriptional regulation of white adipocyte differentiation | |||
3 | Nuclear Receptor transcription pathway | |||
WikiPathways | Wnt Signaling Pathway Netpath | Click to Show/Hide | ||
2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
3 | Differentiation of white and brown adipocyte | |||
4 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
5 | Transcriptional Regulation of White Adipocyte Differentiation | |||
6 | Adipogenesis | |||
7 | SREBP signalling | |||
8 | Nuclear Receptors |
